HNS1p | Doctor/Nurse | Routine visit | High users | Presence of an inhibitor | 0 |
HNS2p | MDT | Routine visit | Product withdrawal | Presence of an inhibitor | 0 |
HNS3 | MDT | Routine visit | High users | None | 0 |
HNS4 | MDT | Routine visit | High users | History of an inhibitor | 0 |
HNS5 | MDT | Routine visit | Volume target (ReFacto FuseNGos patients) | Presence of an inhibitor | 0 |
HNS6 | Nurse | Routine visit | High users | None | 0 |
HNS7 | MDT | Routine visit | High users | Those pending surgery | 1 who was new to prophylaxis |
HNS8p | MDT | Routine visit | High users | <50 exposure days | 2 inhibitor concern |
HNS9 | Doctor/Nurse | Routine visit | High users | Patients who had switched too often | 2 inhibitor concern |
HNS10 | MDT | Letter (unless due in clinic) | Product withdrawal | <50 exposure days | 0 |
HNS11 | Nurse | Letter/phone call | High users | Presence of an inhibitor | 0 |
HNS12 | Doctor | Routine visit | Product withdrawal | Presence of an inhibitor | 0 |
HNS1p | 3 | 0 | Nurse | Assessed by phone | Minimal (low patient numbers) | ||
HNS2p | 3 | On 1 patient | Comparable | Usual 6 months | Nurse | Instruct patient | Minimal (low numbers) |
HNS3 | 15 | On 1 patient | Improved | Usual 6 months | Nurse | 1 day per week for 4 months | |
HNS4 | 30 | 0 | Usual 6 months | Nurse | Instruct patient | 1 day followed by bulk switch | |
HNS5 | 6 | 0 | Only for severe patients | Nurse | Minimal if well planned | ||
HNS6 | ~10 | 0 | Usual 6 months | Nurse | 1–2 days | ||
HNS7 | ~40 | 0 | Usual 6 months | Nurse | Trust | 3–4 days | |
HNS8p | 10 | 0 | Usual 6 months | Nurse | Home delivery company | Minimal (absorbed into general workload) | |
HNS9 | 18 | Only where practical | Comparable | Prior to switch and FU | Nurse | Substantial but absorbed into general workload across the team | |
HNS10 | 8 | 0 | Usual 6 months | Nurse | Trust and Haemtrack | 3 days | |
HNS11 | ~20 | 0 | Usual 6 months | Nurse | |||
HNS12 | ~25 | Yes | Comparable | 6–12 doses | Doctor | Trust | 2–3 days |
Knowledge of products | |
Draw up list of potential patients to switch Highusers On a product that will no longer be available e.g. Helixate On a plasma-derived product and due to switch to recombinant Pendingsurgery Under 50 exposure days Children and parents new to managing home treatment Likely anxiety e.g. extreme worry about treatment safety and the consequences of changing treatment – often with family history of transfusion transmitted disease or inhibitors. Communication issues e.g. learning difficulties, language | |
Agree list of propose patients | |